AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25253199
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy (iCombo)
Trial: 25253199
Drug: Initial monotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial monotherapy (iMono)
Trial: 23173697
Drug: Tradamixina (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tradamixina (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of D‐Glucosamine and N‐Acetyl‐D‐Glucosamine) twice a day for 2 months
Trial: 23173697
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg daily for 2 months
Trial: 20438867
Drug: OAM (Omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM (Omeprazole, Amoxicillin and Metronidazole)
Trial: 17353942
Drug: d-amphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (0.3 mg/kg, given orally) plus a nutritionally balanced amino acid mixture
Trial: 17353942
Drug: L-DOPA (Sinemet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (Sinemet, 2 x 100 mg/25 mg)
Trial: 16223394
Drug: Inferior-medial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inferior-medial injection technique
Trial: 16223394
Drug: Inferior-superior injection
RxNorm normalized name: Sus scrofa superior gastric plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inferior-superior injection technique
Trial: 1922801
Drug: Slow-release bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release bromocriptine (14.2 +/- 0.7 mg/d, taken twice a day)
Trial: 1922801
Drug: Standard bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bromocriptine (13.5 +/- 0.7 mg/d, taken three times a day)
Trial: 6297068
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) + Detorubicin (120 mg/m2, IV every three weeks)
Trial: 6297068
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) alone (250 mg/m2, IV, over 4 days every three weeks)
Trial: 31964380
Drug: AL +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL + day 1 primaquine (0.75 mg/kg)
Trial: 31964380
Drug: AL +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL + day 3 primaquine (0.75 mg/kg)
Trial: 11442551
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin every other day (n = 525)
Trial: 11442551
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin placebo (n = 476)
Trial: 10357955
Drug: Prednisolone 10
RxNorm normalized name: prednisolone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 10 mg at night
Trial: 7498099
Drug: Olestra (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra (24 g) with moderate fibre (7 g/meal)
Trial: 7498099
Drug: Olestra (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra (24 g) with high fibre (24 g/meal)
Trial: 7498099
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with moderate fibre (7 g/meal)
Trial: 7498099
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with high fibre (24 g/meal)
Trial: 7498099
Drug: Olestra (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra (24 g)
Trial: 30951167
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per-oral morphine
Trial: 30951167
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg per-oral naltrexone
Trial: 20696421
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment program (after waitlist)
Trial: 18281409
Drug: Atomoxetine (0.8-1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (0.8-1.8 mg/kg per day)
Trial: 18281409
Drug: Osmotically released
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotically released methylphenidate (18-54 mg/day)
Trial: 1473428
Drug: Low-dose Al
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Al antacid (1 tablet four times a day)
Trial: 76166
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg at bedtime)
Trial: 6426646
Drug: 14 valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 valent pneumococcal vaccine
Trial: 16521845
Drug: CHO (9.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (9.3% carbohydrate solution)
Trial: 16521845
Drug: CHO-PRO (9.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-PRO (9.3% carbohydrate solution plus 1.5% protein)
Trial: 10494641
Drug: Supplementary oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary oxygen (2 L/min)
Trial: 8740798
Drug: Paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel at dose levels of 135, 170, 200, 250, and 300 mg/m2 (24-hour infusion); 250 mg/m2 (one-hour infusion)
Trial: 8740798
Drug: Ifosfamide at
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide at a dose of 1.6 g/m2 i.v. bolus daily for 3 days with mesna uroprotection
Trial: 8391065
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (seven further cycles of CDE: cyclophosphamide 1 g/m2, doxorubicin 45 mg/m2, etoposide 100 mg/m2)
Trial: 8391065
Drug: Follow-up (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up (no further chemotherapy)
Trial: 8391065
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (seven further cycles of CDE)
Trial: 21795458
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Trial: 21795458
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) coadministered with 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Trial: 21795458
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of the seasonal 2009-2010 trivalent nonadjuvanted influenza vaccine (SV)
Trial: 21795458
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of the 2009 monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine (PV) and 2 doses of PV
Trial: 15265241
Drug: telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telithromycin 800 mg once daily for 5, 7, or 10 days
Trial: 15265241
Drug: telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telithromycin 800 mg once daily for 7-10 days
Trial: 15265241
Drug: clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clarithromycin 500 mg twice daily for 10 days
Trial: 8033435
Drug: Control treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatments (anti-cholinesterase drugs, thymectomy, corticosteroids, immunosuppressants, plasma exchange)
Trial: 2645845
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention in place of antihypertensive drugs
Trial: 24640268
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml dexamethasone/bupivacaine/gentamicin (DMG) solution
Trial: 24640268
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml saline solution
Trial: 16167963
Drug: Placebo (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile water in 25 mL saline)
Trial: 2091361
Drug: Citrate-containing glucose
RxNorm normalized name: fructose / glucose / sodium citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate-containing glucose electrolyte solution (GES)
Trial: 2091361
Drug: Maize-salt solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize-salt solution (MSS)
Trial: 381074
Drug: Commercialized anatoxin
RxNorm normalized name: aflatoxin B1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercialized anatoxin (30 Lf per dose, adsorbed on Ca phosphate)
Trial: 381074
Drug: Commercialized anatoxin
RxNorm normalized name: aflatoxin B1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercialized anatoxin (30 Lf per dose, adsorbed on Al hydroxide)
Trial: 381074
Drug: Experimental anatoxin
RxNorm normalized name: aflatoxin B1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental anatoxin (25 Lf per dose, adsorbed on Al phosphate)
Trial: 31035187
Drug: Physostigmine salicylate
RxNorm normalized name: PHYSOSTIGMINE SALICYLATE
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine salicylate (0.04 mg/kg initial dose, followed by continuous infusion of 1 mg/h for 120 h)
Trial: 28450262
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using diode laser 660 nm mediated by methylene blue (MB)
Trial: 28450262
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (kenakort A-orabase)
Trial: 11777865
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g intravenous single dose followed by oral cefixime
Trial: 11777865
Drug: Daily intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravenous dose of 1 g ceftriaxone
Trial: 9693354
Drug: Combined hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormonal replacement therapy
Trial: 9693354
Drug: Sequential hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential hormonal replacement therapy
Trial: 2723991
Drug: Adult surgical
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult surgical services (G-Surg)
Trial: 23010962
Drug: αCa (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: αCa (calcium absorption)
Trial: 16162254
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of 250 mg acetylsalicylic acid + 200 mg paracetamol + 50 mg caffeine (Thomapyrin)
Trial: 16162254
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments except caffeine
Trial: 10439763
Drug: Ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.15 mg/kg as a 5‐mL i.v. injection 5 min before surgery
Trial: 10439763
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 5 mL i.v. at the time of skin closure
Trial: 10439763
Drug: Ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.15 mg/kg i.v. at the time of skin closure
Trial: 8574255
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 200 micrograms (2nd dose if needed)
Trial: 8574255
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 600 micrograms (2nd dose)
Trial: 8574255
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose)
Trial: 8574255
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg + Misoprostol 400 micrograms (1st dose) + Misoprostol 200 micrograms (2nd dose)
Trial: 21385401
Drug: Telemonitoring intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemonitoring intervention (daily self-measurements of respiratory-rate, heart-rate, blood pressure, oxygen saturation, weight, body temperature; daily qualitative symptom questionnaire; routine telephone contacts every fortnight)
Trial: 17261216
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pretreatment of remifentanil (0.35 microg kg(‐1) min(‐1)) and premixture of lidocaine with propofol (1% propofol and 1% lidocaine in a 10:1 ratio)
Trial: 17261216
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (remifentanil and lidocaine)
Trial: 14871466
Drug: anti-TNF-alpha humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-TNF-alpha humanized antibodies (infliximab)
Trial: 3115846
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate transdermal patch (10 mg daily)
Trial: 19539353
Drug: IA-BioHA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA-BioHA (20 mg/2 ml)
Trial: 11844646
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving anesthesia without epidural local anesthetics, postoperative analgesia with epidural morphine, and mobilization without fixed goals
Trial: 10069276
Drug: Sufentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil concentration of 1.5 ng/mL (group L)
Trial: 10069276
Drug: Sufentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil concentration of 3.0 ng/mL (group M)
Trial: 10069276
Drug: Sufentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil concentration of 4.5 ng/mL (group H)
Trial: 10069276
Drug: Sufentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil concentration of 1.7 ng/mL
Trial: 7628181
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg midazolam
Trial: 31858732
Drug: Small Changes
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small Changes (SC; make small daily changes in intake and activity)
Trial: 25918933
Drug: Curcumin (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (45 mg/day) for 14 days before surgery
Trial: 19237785
Drug: Single-stage adjustable
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stage adjustable strabismus surgery (SSASS) under topical anesthesia and intravenous conscious sedation
Trial: 14660132
Drug: Naloxone bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone bolus administered under anaesthetic
Trial: 9032593
Drug: Fluconazole monotherapy
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole monotherapy
Trial: 1355923
Drug: Idazoxan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (20 mg, 40 mg, 80 mg)
Trial: 30146783
Drug: Nitrogen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen plasma treatment on one side of periorbital wrinkles with three sessions at a three-week interval
Trial: 30146783
Drug: Nitrogen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen plasma treatment
Trial: 30146783
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (contralateral side without treatment)
Trial: 27701661
Drug: OnabotulinumtoxinA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (200 U, cystoscopic intradetrusor injection)
Trial: 25000668
Drug: Test dentifrice
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test dentifrice containing 1.5% arginine, an insoluble calcium compound and 1,450 ppm fluoride
Trial: 11844821
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered eniluracil and 5-FU (1.0 mg/m2 with eniluracil in a 10:1 ratio, twice daily for 28 days)
Trial: 10544991
Drug: Integrated drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated drug and alcohol intervention (IDAI)
Trial: 30975525
Drug: PCV10 (two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV10 (two-dose schedule, group D)
Trial: 27753182
Drug: transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal oestradiol (tE2)
Trial: 27753182
Drug: luteinising hormone-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: luteinising hormone-releasing hormone agonists (LHRHa)
Trial: 24678746
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine 2.5% solution irrigation
Trial: 24678746
Drug: Preservative-free artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free artificial tears and preservative-free antibiotic drops (without povidone iodine)
Trial: 10713313
Drug: 3.8 g
RxNorm normalized name: dextrin 3 gram/3.8 gram ORAL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.8 g eicosapentaenoic acid/d
Trial: 10713313
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g docosahexaenoic acid/d
Trial: 10713313
Drug: 4.0 g
RxNorm normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g corn oil/d (placebo)
Trial: 2867396
Drug: Oral immunisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunisation with killed Haemophilus influenzae
Trial: 29280191
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements (at least 50% of the recommended dose)
Trial: 24853829
Drug: Serial clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial clopidogrel dose adjustment based on platelet function testing (PFT) during 12 months of dual antiplatelet therapy (DAPT). Patients took up to two additional 600 mg loading doses and a maintenance dose of 75-300 mg.
Trial: 24853829
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment without dose adjustment).
Trial: 24853829
Drug: Interventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional group (with dose adjustment).
Trial: 20562076
Drug: 50 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU/kg heparin with an upper limit of 5,000 IU
Trial: 20562076
Drug: 5,000 IU
RxNorm normalized name: bleopmycin 15,000 IU Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU heparin (standard dose)
Trial: 17722960
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone furoate 110 microg once daily for 2 weeks in adults and adolescents with seasonal allergic rhinitis
Trial: 17722960
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone furoate 110 microg once daily for 4-6 weeks in adults and adolescents with perennial allergic rhinitis
Trial: 17722960
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone furoate nasal spray in children aged 6-11 years for 2 weeks for seasonal allergic rhinitis
Trial: 17722960
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone furoate nasal spray in children aged 6-11 years for 4 weeks for perennial allergic rhinitis
Trial: 17722960
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray in adults, adolescents and children aged 2-11 years
Trial: 15792815
Drug: 1500 mcg
RxNorm normalized name: cyanocobalamin 1500 MCG Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mcg mecobalamin daily for 2 years